Prelude Therapeutics (PRLD)
1.04
0.02 (1.96%)
At close: Jan 15, 2025, 2:30 PM
undefined% (undefined)
| Bid | 1.02 |
| Market Cap | 57.24M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.77 |
| PE Ratio (ttm) | -0.59 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.06 |
| Volume | 2,262 |
| Avg. Volume (20D) | 497,470 |
| Open | 1.02 |
| Previous Close | 1.02 |
| Day's Range | 1.02 - 1.04 |
| 52-Week Range | 0.80 - 6.80 |
| Beta | undefined |
About PRLD
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selecti...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 25, 2020
Employees 128
Stock Exchange NASDAQ
Ticker Symbol PRLD
Website https://www.preludetx.com
Analyst Forecast
According to 2 analyst ratings, the average rating for PRLD stock is "Buy." The 12-month stock price forecast is $4.5, which is an increase of 332.69% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
11 months ago ·
Source
+33.05%
Prelude Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
